



DEPARTMENT OF HEALTH & HUMAN SERVICES

MAY 10 2010

Food and Drug Administration
Rockville MD 20857

Re: SABRIL
Docket No. FDA-2010-E-0021

The Honorable David J. Kappos
Undersecretary of Commerce for Intellectual Property
• Director of the United States Patent and Trademark Office
Mail Stop Hatch-Waxman PTE
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Director Kappos:

This is in regard to the application for patent term extension for U.S. Patent No. 5,380,936 filed by Lundbeck Inc., under 35 U.S.C. § 156. The human drug product claimed by the patent is SABRIL (vigabatrin), which was assigned new drug application (NDA) Nos. 22-006 and 20-427.


A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product, as defined under 35 U.S.C. § 156(f)(1).

The NDAs were both approved on August 21, 2009, which makes the submission of the patent term extension application on Monday, October 19, 2009, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the *Federal Register*, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely yours,



Jane A. Axelrad
Associate Director for Policy
Center for Drug Evaluation and Research

cc: Edward P. Gamson
Husch, Blackwell, Sanders, Welsh & Katc, Ltd.
120 S. Riverside Plaza, 22nd Floor
Chicago, IL 60606